Pharmacokinetic Considerations in the Treatment of Attention-Deficit Hyperactivity Disorder with Methylphenidate

ISSN： 1172-7047

Source： CNS Drugs, Vol.18, Iss.4, 2004-01, pp. : 243-250

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cardiovascular Effects of Methylphenidate, Amphetamines and Atomoxetine in the Treatment of Attention-Deficit Hyperactivity Disorder

By Stiefel Gary

Drug Safety, Vol. 33, Iss. 10, 2010-10 ,pp. : 821-842

Adis International

Access to resources Recommend Favorite

Pharmacokinetic and Pharmacodynamic Drug Interactions in the Treatment of Attention-Deficit Hyperactivity Disorder

By Markowitz J.S. Patrick K.S.

Clinical Pharmacokinetics, Vol. 40, Iss. 10, 2001-01 ,pp. : 753-772

Adis International

Access to resources Recommend Favorite

Methylphenidate and its Isomers: Their Role in the Treatment of Attention-Deficit Hyperactivity Disorder Using a Transdermal Delivery System

By Heal David J.

CNS Drugs, Vol. 20, Iss. 9, 2006-01 ,pp. : 713-738

Adis International

Access to resources Recommend Favorite

Spotlight on Methylphenidate Controlled-Delivery Capsules (Equasym™XL, Metadate CD™) in the Treatment of Children and Adolescents with Attention-Deficit Hyperactivity Disorder

By Anderson Vanessa R. Keating Gillian M.

CNS Drugs, Vol. 21, Iss. 2, 2007-01 ,pp. : 173-175

Adis International

Access to resources Recommend Favorite

Methylphenidate Transdermal System: In Attention-Deficit Hyperactivity Disorder in Adolescents

By Keating Gillian M.

CNS Drugs, Vol. 25, Iss. 4, 2011-04 ,pp. : 333-342

Adis International

Access to resources Recommend Favorite